Natalizumab biosimilar - BioXpress Therapeutics

Drug Profile

Natalizumab biosimilar - BioXpress Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BioXpress Therapeutics
  • Class Antineoplastics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Switzerland (IV, Infusion)
  • 22 Aug 2013 Preclinical trials in Multiple sclerosis in Switzerland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top